CONTROLLING THE HIV EPIDEMIC WITH

ANTIRETROVIRALS



Having the Courage of Our Convictions

STRATEGIC LESSONS FROM THE FRONTLINES







From home-based testing to ART

Implementation lessons: ANRS 12249 TasP in South Africa

François DABIS, MD, PhD Université de Bordeaux

François dabis@u-bordeaux.fr



Main hypothesis (formulated in 2010)

Universal Test and Treat

i.e. HIV testing of <u>all</u> adult members of a community, followed by <u>immediate</u> ART initiation of <u>all</u> of those identified as HIV-infected (regardless of immunological or clinical staging)


will prevent onward transmission and reduce HIV incidence in this population

ANRS 12 249 TasP trial design

- Cluster randomized trial
 - Cluster = a population of approx. 1,250 adults (16+ years)
- In all clusters, rounds of home-based HIV testing repeated every ~ 6 months
- All HIV+ identified participants are referred to local TasP clinics (at least one clinic per cluster)

Control clusters	Intervention clusters
ARV treatment according to South African guidelines (<350 CD4 or WHO stage 3 or 4) (since Jan. 2015, <500 CD4)	ARV treatment regardless of CD4 or clinical staging

Where the trial takes place Hlabisa



Hlabisa - Understanding the context

Rural area with scattered housing





- One of the poorest areas in South Africa
 - → 2011 *national census*: 43 % unemployment
- Migration ++ to cities (studying, work, ...)

Hlabisa sub-District Descriptive epidemiology of HIV infection

- Prevalence in 2011: >29 % among the 15-49 years old
- Important disparities by age and gender

	P	6 7
15-19 yrs	14.7 %	7.0 %
20-24 yrs	26.5 %	10.2 %
25-29 yrs	38.3 %	16.0 %
30-34 yrs	47.1 %	27.3 %
35-39 yrs	50.4 %	32.0 %
40-44 yrs	49.1 %	35.8 %
45-49 yrs	50.3 %	39.1 %

(Zaidi et al, 2013)

HOME-BASED HIV TESTING

What is it? Why? How?

Some lessons learnt in the ANRS 12249 TasP trial: feasibility, acceptability and subsequent linkage to care

Home-based HIV testing Principles

• To offer rapid HIV testing at home to all adult members residing in a community by dedicated counsellors



When agreed, choose a place to respect privacy

Test procedure

- -Pre-test counselling
- -Rapid HV test
- -Post-test counselling

HIV+ referred to clinic









Home-based HIV testing Is it appropriate for implementing and evaluating a TasP intervention?

- Recommended by WHO to increase the HIV testing coverage, especially when:
 - Prevalence of HIV is high
 - Access to HIV counselling and testing services is sub-optimal
 - Hlabisa:
 - Rural area → difficulties to access all health services
 - HIV test often but not systematically proposed in primary health care services
- Home-based testing already introduced and evaluated in 2009-2011 by local authorities. Good acceptance by the population.
 - Maheswaran et al, JAIDS 2012

Home-based testing Specificities in the context of the TasP trial

Repeat offer of HIV testing

- At home
- Every six months
- To all adults ≥16 years residing in the study area
- By counsellors trained for and by the trial
- In parallel, biomedical and social science data collection at each survey round for research purposes by trial staff:
 - Blinded DBS (Dry Blood Spot) to estimate HIV incidence in the population
 - Socio-demographic and economic questionnaires

Home-based HIV testing What have we learnt within the TasP trial based on data collected in 2012-2014?

1. This home-based approach is quite acceptable

Poster Larmarange et al (R4P 2014) 2. Referring those identified HIV+ to clinics is not a straightforward exercise

Oral presentation
Plazy et al
(IAS 2015)

Home-based HIV testing is acceptable in TasP

- Eligible population: 12 894
- 25 % could not be contacted
 - Limited demographic data and reasons remain largely unknown
- Good acceptance of home-based HIV testing by those ever contacted:
 - At first contact: $\approx 77 \%$
 - At second contact:


Among those HIV-neg at first contact: >85 % → repeat testing Among those who had refused the first contact/test: >47 %

Acceptance more limited by

- -Men
- -20-30 years
- Good opportunity to re-identify those already known as HIVpos to offer them a second chance to refer them to clinic
 - ≈ 30 % of the HIV-pos had already been diagnosed and half of them had used at least once the local HIV program

Home-based HIV testing provides partial opportunities to link PLWHIV into care

- <u>Eligible population</u>: 1 323 individus identified HIV+, had never been in care before, and now referred to clinic
 - Followed up \geq 3 months and not deceased
- <38 % will use a clinic at least once (TasP clinic or DoH local clinic within 3 months after having being invited for referral



No statistical difference

- By sex
- By study arm


Those who link the least:

- < 30 years
- Students
- DNK HIV-pos in the family
- No history of referral
- Distance to clinic >1km

DISCUSSION & CONCLUSIONS

What is the contribution and limits of a strategy starting by home-based HIV testing to reach the first 90 and ultimately the 90 x 90 90 UNAIDS targets?

Discussion & Conclusions (1)



- Home-based HIV testing has clear advantages and provides benefits
 - Well accepted by this population (>77 %)
 - Allows the re-identification of HIV+ individuals previously diagnosed but not in care (never before or who dropped momentarily)
 - → An efficacious intervention that will maximize the number of PLWHIV aware of their status and is likely to be necessary ... but this is not the magic bullet

Discussion & Conclusions (2)

- Home-based HIV testing suffers some limitations
 - 25 % of the « residents » remain uncontacted
 - → More testing services should be available at any point in time in the community (mobile testing is one of them)
 - Linkage to HIV care within a reasonable time window remains sub-optimal after repeat home-based HIV testing is offered as a central testing strategy (<40 % within 3 months after referral)
 - → Need to put in place at large scale and evaluate a comprehensive combination of interventions proven independantly to contribute to the 90 X 90 X strategy (mobile telephones and SMS reminders, community health workers and peer navigators, home-based ART initiation,



GUIDELINES



GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV

SEPTEMBER 2015

Ngiyabonga! Merci!

- Special thanks to Mélanie Plazy, Joanna Orne-Gliemann, Joseph Larmarange and Collins Iwuji
- Deenan Pillay and the Africa Centre for Health and **Population Studies**
- Trial participants
- Department of Health of KZN & RSA
- Merck/Gilead









